Engineered Phagemids for Nonlytic, Targeted Antibacterial Therapies
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The increasing incidence of antibiotic-resistant bacterial infections is creating a global public health threat. Because conventional antibiotic drug discovery has failed to keep pace with the rise of resistance, a growing need exists to develop novel antibacterial methodologies. Replication-competent bacteriophages have been utilized in a limited fashion to treat bacterial infections. However, this approach can result in the release of harmful endotoxins, leading to untoward side effects. Here, we engineer bacterial phagemids to express antimicrobial peptides (AMPs) and protein toxins that disrupt intracellular processes, leading to rapid, nonlytic bacterial death. We show that this approach is highly modular, enabling one to readily alter the number and type of AMPs and toxins encoded by the phagemids. Furthermore, we demonstrate the effectiveness of engineered phagemids in an in vivo murine peritonitis infection model. This work shows that targeted, engineered phagemid therapy can serve as a viable, nonantibiotic means to treat bacterial infections, while avoiding the health issues inherent to lytic and replicative bacteriophage use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?
Brogden, K. A. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1098 · Cited by 5,829
Dethlefsen, L., & Relman, D. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000087107 · Cited by 2,421
Automated design of synthetic ribosome binding sites to control protein expression
Salis, H. M., Mirsky, E. A., & Voigt, C. A. (2009) · Nature Biotechnology · doi:10.1038/nbt.1568 · Cited by 1,844
Dispersing biofilms with engineered enzymatic bacteriophage
Lu, T. K., & Collins, J. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704624104 · Cited by 895
Self-citationAntibiotics and the Gut Microbiota
Modi, S. R., Collins, J. J., & Relman, D. A. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72333 · Cited by 667
Self-citation
Cited by
Alternatives to Conventional Antibiotics in the Era of Antimicrobial Resistance
Ghosh, C., Sarkar, P., Issa, R., & Haldar, J. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2018.12.010 · Cited by 661
Recent progress in targeted delivery vectors based on biomimetic nanoparticles
Chen, L., Hong, W., Ren, W., Xu, T., Qian, Z., & He, Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00631-2 · Cited by 374
Microbiome therapeutics — Advances and challenges
Mimee, M., Citorik, R. J., & Lu, T. K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.032 · Cited by 317
Dong, X., Pan, P., Zheng, D.-W., Bao, P., Zeng, X., & Zhang, X.-Z. (2020) · Science Advances · doi:10.1126/sciadv.aba1590 · Cited by 282
Next-generation biocontainment systems for engineered organisms
Lee, J. W., Chan, C. T. Y., Slomovic, S., & Collins, J. J. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0056-x · Cited by 270
Self-citation
Metadata
- Authors
- Krom, R. J., Bhargava, P., Lobritz, M. A., & Collins, J. J.
- Venue
- Nano Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-06-08
- Volume
- 15
- Issue
- 7
- Pages
- 4808-4813
- ISSN
- 1530-6984 (ISSN-L)
- 1530-6992
- OpenAlex
- W2474793623
- Cited by
- 108
- References
- 5
- FWCI
- 9.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.